UK markets closed

HYLORIS PHARMA. S.A. (52U.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
13.60+0.10 (+0.74%)
At close: 3:46PM CEST
Full screen
Previous close13.50
Open13.55
Bid0.00 x N/A
Ask0.00 x N/A
Day's range13.55 - 13.75
52-week range9.00 - 14.40
Volume15
Avg. volume27
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Globe Newswire

    Hyloris Acquires Breakthrough, Patented Technology to Develop and Market Aspirin IV in the U.S. in Acute Coronary Syndrome

    Potential to revolutionise the current treatment paradigm and become the cornerstone therapy for patients with suspected acute coronary syndromeEnables accelerated development of HY-073 (IV acetylsalicylic acid), bringing the anticipated FDA submission date forward to end 2023Initially targeting a total addressable patient population of ~2 million in the U.S. Liège, Belgium – 13 October 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to address

  • Globe Newswire

    Hyloris Expands Cardiovascular Pipeline with Breakthrough Extended-Release Milrinone Capsule in Late-Stage Heart Failure

    Patient-friendly alternative to continuous IV administration – proven safety and efficacyTargeting orphan, late-stage heart failure indication with high unmet medical needs Liège, Belgium – 8 October 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it has acquired the global rights from the Baker Heart and Diabetes Institute (“the Baker Institute”),

  • Globe Newswire

    Hyloris Appoints Jean-Luc Vandebroek as Chief Financial Officer

    Brings >25 years of executive financial leadership Liège, Belgium – 23 September 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that Jean-Luc Vandebroek will be joining the Company as its Chief Financial Officer. In addition to his new role at Hyloris, Jean-Luc will remain Non-Executive Director of the Board of Bone Therapeutics during a transition peri